Japan - enska - すりの適正使用協議会 RAD-AR Council, Japan

nippon-chemiphar co.,ltd - azilsartan - faint yellowish red tablet, diameter 5.6 mm, thickness 2.8 mm

Japan - enska - すりの適正使用協議会 RAD-AR Council, Japan

nippon-chemiphar co.,ltd - azilsartan - yellow tablet, diameter 8.1 mm, thickness 3.6 mm

Japan - enska - すりの適正使用協議会 RAD-AR Council, Japan

teva takeda pharma ltd. - azilsartan - faintly yellowish red tablet, major axis: 8.2 mm, minor axis: 4.7 mm, thickness: approx. 3.1 mm

Japan - enska - すりの適正使用協議会 RAD-AR Council, Japan

teva takeda pharma ltd. - azilsartan - faintly red tablet, major axis: 9.1 mm, minor axis: 5.1 mm, thickness: approx. 3.3 mm

Japan - enska - すりの適正使用協議会 RAD-AR Council, Japan

teva takeda pharma ltd. - azilsartan - yellow tablet, major axis: 9.1 mm, minor axis: 5.1 mm, thickness: approx. 3.3 mm

Ísrael - enska - Ministry of Health

truemed ltd, israel - pitolisant as hydrochloride - film coated tablets - pitolisant as hydrochloride 17.8 mg - pitolisant - wakix is indicated• in adults for the treatment of narcolepsy with or without cataplexy. • to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa) whose eds has not been satisfactorily treated by, or who have not tolerated, osa primary therapy, such as continuous positive airway pressure (cpap).

Ísrael - enska - Ministry of Health

truemed ltd, israel - pitolisant as hydrochloride - film coated tablets - pitolisant as hydrochloride 4.45 mg - pitolisant - wakix is indicated• in adults for the treatment of narcolepsy with or without cataplexy. • to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa) whose eds has not been satisfactorily treated by, or who have not tolerated, osa primary therapy, such as continuous positive airway pressure (cpap).

Evrópusambandið - enska - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastic agents - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy.in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).

Evrópusambandið - enska - EMA (European Medicines Agency)

dynavax gmbh - hepatitis b surface antigen - hepatitis b - vaccines - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations.it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Írland - enska - HPRA (Health Products Regulatory Authority)

laboratorios hipra s.a. - live attenuated prrsv, strain vp-046 bis - lyophilisate and solvent for suspension for injection - 10(3.5) - 10(5.5) cell culture infective dose 50/dose - porcine reproductive and respiratory syndrome (prrs) virus - pigs - immunological - live vaccine